Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EHAB 
Enhabit Inc. (EHAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: EHAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.38
1 Year Target Price $9.38
| 1 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.51% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 405.52M USD | Price to earnings Ratio - | 1Y Target Price 9.38 |
Price to earnings Ratio - | 1Y Target Price 9.38 | ||
Volume (30-day avg) 5 | Beta 1.3 | 52 Weeks Range 6.47 - 10.90 | Updated Date 08/29/2025 |
52 Weeks Range 6.47 - 10.90 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.66 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate 0.1 | Actual 0.13 |
Profitability
Profit Margin -12.84% | Operating Margin (TTM) 6.28% |
Management Effectiveness
Return on Assets (TTM) 2.61% | Return on Equity (TTM) -20.37% |
Valuation
Trailing PE - | Forward PE 16.39 | Enterprise Value 897167825 | Price to Sales(TTM) 0.39 |
Enterprise Value 897167825 | Price to Sales(TTM) 0.39 | ||
Enterprise Value to Revenue 0.86 | Enterprise Value to EBITDA 14.43 | Shares Outstanding 50690400 | Shares Floating 40188856 |
Shares Outstanding 50690400 | Shares Floating 40188856 | ||
Percent Insiders 3.4 | Percent Institutions 101.9 |
Upturn AI SWOT
Enhabit Inc.
Company Overview
History and Background
Enhabit, Inc. spun off from Encompass Health in July 2022. It focuses on providing home health and hospice services.
Core Business Areas
- Home Health: Provides skilled nursing, therapy, and other medical services to patients in their homes.
- Hospice: Offers end-of-life care, including pain management, emotional support, and spiritual guidance, to patients and their families.
Leadership and Structure
Barbara Jacobsmeyer serves as the CEO. The company has a typical corporate structure with executive leadership overseeing various departments.
Top Products and Market Share
Key Offerings
- Home Health Services: Includes skilled nursing, physical therapy, occupational therapy, speech therapy, medical social services, and home health aides. Market share data is not readily available, but the home health industry is fragmented. Competitors include Amedisys (AMED) and LHC Group (LHCG), now part of Optum.
- Hospice Services: Offers palliative care, symptom management, emotional and spiritual support, and bereavement services. Market share data is also fragmented. Competitors include Amedisys (AMED) and LHC Group (LHCG), now part of Optum.
Market Dynamics
Industry Overview
The home health and hospice industry is experiencing growth due to the aging population, increasing prevalence of chronic diseases, and a preference for receiving care at home.
Positioning
Enhabit is a major player in the home health and hospice market, offering a comprehensive range of services. It competes on quality of care, geographic reach, and relationships with referral sources.
Total Addressable Market (TAM)
The TAM for home health and hospice care is estimated to be hundreds of billions of dollars annually. Enhabit is well-positioned to capture a significant share of this market due to its established presence and broad service offerings.
Upturn SWOT Analysis
Strengths
- Established brand name
- Extensive network of locations
- Comprehensive range of services
- Experienced management team
Weaknesses
- Exposure to regulatory changes
- Labor shortages
- Dependence on Medicare and Medicaid reimbursement
- High employee turnover
Opportunities
- Expanding service offerings
- Acquiring smaller competitors
- Leveraging technology to improve efficiency
- Increasing penetration in existing markets
Threats
- Increased competition
- Declining reimbursement rates
- Cybersecurity risks
- Economic downturn
Competitors and Market Share
Key Competitors
- AMED
- LHCG
Competitive Landscape
Enhabit faces competition from other large national providers, regional players, and local agencies. Its ability to differentiate through quality, service, and technology will be crucial for success.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited since the spin-off in 2022. Focus on recent quarters and years for meaningful trends.
Future Projections: Future projections would require analyst estimates. Look for expert consensus targets.
Recent Initiatives: Enhabit has focused on optimizing operations, improving patient outcomes, and expanding its geographic footprint.
Summary
Enhabit is a relatively new standalone company in the growing home health and hospice market. While it has a strong foundation due to its established operations, it faces challenges related to competition and reimbursement rates. Future success will depend on its ability to innovate and adapt to changing market conditions and capture market share from its competitors. Recent initiatives around optimization and technology are keys to its long-term health.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings, Industry reports, Analyst research
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enhabit Inc.
Exchange NYSE | Headquaters Dallas, TX, United States | ||
IPO Launch date 2022-07-01 | President, CEO & Director Ms. Barbara Ann Jacobsmeyer B.S., M.A., P.T. | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 10600 | Website https://www.ehab.com |
Full time employees 10600 | Website https://www.ehab.com | ||
Enhabit, Inc. provides home health and hospice services in the United States. The company's home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. It also provides hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.